Associations of neuralgic amyotrophy with COVID-19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database
- 주제(키워드) COVID-19 , neuralgic amyotrophy , Parsonage-Turner syndrome , SARS-CoV-2 , vaccination
- 등재 SCIE, SCOPUS
- 발행기관 John Wiley and Sons Inc
- 발행년도 2022
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000203171
- 본문언어 영어
- Published As https://doi.org/10.1002/mus.27734
- PubMed https://pubmed.ncbi.nlm.nih.gov/36214181
초록/요약
Introduction/Aims: There are limited studies on the association of COVID-19 vaccination with neuralgic amyotrophy (NA). Therefore, we evaluated the association between COVID-19 vaccination and the occurrence of NA. Methods: We explored unexpected safety signals for NA related to COVID-19 vaccination through disproportionality analysis using VigiBase, the World Health Organization's pharmacovigilance database. Results: On October 15, 2021, 335 cases of NA were identified in the database. The median time to onset of NA after vaccination was around 2 weeks. A significant signal of disproportionality of NA was observed for the ChAdOx1 nCoV-19 vaccine (AstraZeneca) (information component [IC]025 = 0.33, reporting odds ratio [ROR]025 = 1.30) and two mRNA-based COVID-19 vaccines (BNT162b2 [Pfizer and BioNTech] and mRNA-1273 [Moderna]) (IC025 = 1.74, ROR025 = 3.82) compared with the entire database. However, when compared with influenza vaccines, we did not detect any signal of disproportionality of NA for both the ChAdOx1 nCoV-19 vaccine (IC025 = −2.71, ROR025 = 0.05) and mRNA-based COVID-19 vaccines (IC025 = −1.38, ROR025 = 0.13). Discussion: A weak association was observed between NA and COVID-19 vaccines. However, the risk did not surpass that of influenza vaccines. © 2022 Wiley Periodicals LLC.
more